Clinical trial Recruiting at 2 sites Observational Ages Any age to 12 Months

Early warning system for neonatal NEC to help predict risk in very preterm babies

Official title: Construction of a Multidimensional Dynamic Early Warning System for Genetic-Immune-Inflammatory Disorders in Precision Prevention and Control of Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study

Run by Guangzhou Women and Children's Medical Center · NCT07545993 · Data updated 2026-11-12

A multicenter observational study in preterm newborns to see if combining genetic data and immune markers with clinical info can better predict necrotizing enterocolitis than clinical data alone.

Quick facts

Study typeObservational
AgesAny age to 12 Months
SexAll
Enrollment1050 (estimated)
SponsorGuangzhou Women and Children's Medical Center
Academic / other
Locations2 sites (Guangxi, Guangxi and 1 other locations)
StatusRecruiting
StartedApril 20, 2026
Main results expectedDecember 31, 2029
Study endsDecember 31, 2029
Registry record updatedNovember 6, 2026
Trial IDNCT07545993 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Very preterm infants born before 32 weeks gestation admitted to one of the three participating NICUs with available perinatal and hospitalization data.

Probably not a fit

Newborns without genetic data availability or those not meeting inclusion criteria may not receive added predictive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study develops and tests a prediction model for necrotizing enterocolitis (NEC) in preterm infants. It uses retrospective data and prospective validation across three hospitals to see if genetic susceptibility and longitudinal immune/inflammatory markers add value beyond clinical factors. The development phase leverages an existing exome sequencing cohort, with internal and temporal validations, followed by geographic external validation and a future prospective cohort. The study does not involve an intervention; it aims to improve early risk prediction to support clinical decision-making. Records from the same infant are kept in a single cohort to avoid overlap, with careful checks for duplicates.

Why it matters

Potential benefit: If successful, the model could enable earlier identification of high-risk infants and inform personalized monitoring or intervention strategies.

How similar studies have gone: Previous work suggests that combining genetic and immune markers with clinical data can improve risk prediction in neonatal conditions, but this specific approach for NEC is being tested in this multicenter study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Birth before 32 completed weeks of gestation.
* Admission to the neonatal department of one of the three participating hospitals.
* Availability of perinatal and hospitalization information required by the approved cohort-specific data collection plan.
* For the development cohort, clinical exome sequencing performed during the neonatal hospitalization.
* For retrospective validation cohorts, available clinical records and extractable longitudinal complete blood count data.
* For the prospective cohort, written permission from a parent or legally authorized guardian for participation and for the use of residual blood for genetic analysis as required by the approved protocol.

Exclusion Criteria:

* Congenital malformations, a defined clinical syndrome, or a chromosomal abnormality meeting the exclusion definition in the approved protocol.
* Death or discharge against medical advice within the first 7 days after birth.
* A confirmed pathogenic genetic diagnosis that explains the main clinical phenotype.
* An additional infant from the same monozygotic multiple birth when one infant from that pregnancy has already been selected for analysis according to the prespecified selection rule.

Where it's running

  • Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region.
    Guangxi, Guangxi, China
    Recruiting
  • Northwest Women's and Children's Hospital
    Xi’an, Shanxi, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.